<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01855945</url>
  </required_header>
  <id_info>
    <org_study_id>V129_01</org_study_id>
    <nct_id>NCT01855945</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to &lt;9 Years, Adolescents 9 to &lt;18 Years, Adults 18 to &lt;65 Years and Elderly 65 Years and Older.</brief_title>
  <official_title>Phase I Multi-center, Observer-Blind, Randomized, Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated Novel Swine Origin A/H3N2v Monovalent Subunit Influenza Virus Vaccine (H3N2c) in Children Ages 3 to &lt;9 Years, Adolescents 9 to &lt;18 Years, Adults 18 to &lt; 65 Years and Elderly ≥ 65 Years and Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in
      children ages 3 to &lt;9 years, adolescents 9 to &lt;18 years, adults 18 to &lt;65 years and elderly
      65 years and older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects (3 to &lt;9 Years of Age) Reporting Solicited Adverse Events (AEs) Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 1 through Day 7 after each vaccination</time_frame>
    <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (3 to &lt;9 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects (9 to &lt;18 Years of Age) Reporting Solicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 1 through Day 7 after each vaccination</time_frame>
    <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (9 to &lt;18 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects (18 to &lt; 65 Years) Reporting Solicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 1 through Day 7 after each vaccination</time_frame>
    <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (18 to &lt; 65 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects (≥ 65 Years) Reporting Solicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 1 through Day 7 after each vaccination</time_frame>
    <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (≥ 65 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects (3 to ≥ 65 Years of Age) Reporting Unsolicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 1 through Day 366</time_frame>
    <description>The number of subjects reporting any unsolicited adverse events (AEs) from day 1 through day 21 after last vaccination within each vaccine group are reported.
The number of subjects reporting any serious adverse events (SAEs), AEs leading to withdrawal from the study, medically attended AEs, AE of special interest (AESI), new onset chronic disease (NOCDs) from day 1 through day 366, after receiving with H3N2 monovalent vaccine are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects (3 to ≥ 65 Years of Age) With Seroconversion or Significant Increase in Hemagglutination Inhibition (HI) Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 22, Day 43 post vaccination</time_frame>
    <description>The percentages of subjects (3 to ≥ 65 years of age) achieving seroconversion or significant increase in HI antibody titers against H3N2 homologous strain, three weeks after receiving first (Day 22) and second (Day 43) vaccination are reported.
Seroconversion is defined as HI titer ≥1:40 for subjects negative at baseline (HI titer &lt;1:10); or a minimum 4-fold increase in HI titer for subjects positive at baseline (HI titer ≥1:10) on Day 22 and Day 43.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects (3 to ≥ 65 Years of Age) Achieving HI Titers ≥1:40 Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 1, Day 22, Day 43 post vaccination</time_frame>
    <description>The percentages of subjects (3 to ≥ 65 years of age) achieving HI titers ≥1:40 against H3N2 homologous strain at baseline (Day 1) and three weeks after receiving first (Day 22) and second (Day 43) vaccination are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean HI Antibody Titers (GMTs) Following Vaccination With H3N2 Monovalent Vaccine (3 to ≥ 65 Years of Age).</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 183 and Day 366 post vaccination</time_frame>
    <description>The HI antibody titers against H3N2 homologous strain at baseline (Day 1), three weeks after first (Day 22) and second (Day 43) vaccination and persisting titers at six months (Day 183) and one year (Day 366) after vaccination are reported in terms of GMTs is reported across subjects with age groups 3 to ≥ 65 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio of Subjects (3 to ≥ 65 Years of Age) Post Versus Pre-vaccination HI Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 22/Day 1, Day 43/Day 1, Day 183/Day 1, Day 366/Day 1</time_frame>
    <description>The geometric mean ratio (GMR) of post versus pre-vaccination HI antibody titers against H3N2 homologous strain following vaccination as compared to baseline titers are reported for after first (Day 22/Day 1) and second (Day 43/Day 1) vaccination and for persisting titers at six months (Day 183/Day1) and one year (Day 366/Day 1) is reported across subjects with age groups 3 to ≥ 65 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (3 to ≥ 65 Years of Age) Achieving HI Titers ≥1:40 Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 183 and Day 366 post vaccination</time_frame>
    <description>The percentages of subjects (3 to ≥ 65 years of age) demonstrating HI titers ≥1:40 against H3N2 homologous strain on Day 183 and Day 366 post vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (3 to ≥ 61 Years of Age) With Seroconversion or Significant Increase in Hemagglutination Inhibition Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 22, Day 43 post vaccination</time_frame>
    <description>The percentage of subjects achieving seroconversion or significant increase for HI antibody titers at three weeks after receiving first (Day 22) and second (Day 43) vaccination is reported, across age groups of 3 to ≥61 years.
Seroconversion is defined as HI titer ≥1:40 for subjects negative at baseline (HI titer &lt;1:10); or a minimum 4-fold increase in HI titer for subjects positive at baseline (HI titer ≥1:10) on Day 22 and Day 43.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (3 to ≥ 61 Years of Age) Achieving HI Titers ≥1:40 Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 1, Day 22, Day 43 post vaccination</time_frame>
    <description>The percentages of subjects achieving HI titers ≥1:40 against H3N2 homologous strain at three weeks after receiving first (day 22) and second (day 43) vaccination, is reported across age groups of 3 to ≥ 61 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMR in Subjects (3 to ≥ 61 Years of Age) of Post-vaccination Versus Pre-vaccination HI Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</measure>
    <time_frame>Day 22/Day 1, Day 43/Day 1, Day183/ Day 1, Day 366/Day 1</time_frame>
    <description>GMR of post-vaccination versus pre-vaccination HI GMTs following vaccination with H3N2 monovalent vaccine is reported across subjects with age groups 3 to ≥ 61 years.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">627</enrollment>
  <condition>Prophylaxis of A/H3N2v Influenza</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.75 µg H3N2c HA + 0.125 mL MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 µg H3N2c HÁ + 0.250 mL MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 µg H3N2c unadjuvanted</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Swine Influenza</intervention_name>
    <description>Comparison of different dosages of vaccines</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females 3 years of age and older

          2. Individuals or, (for children and adolescents) parents or legal guardians, who have
             given written consent after the nature of the study has been explained according to
             local regulatory requirements. Assent is required depending on age of child/adolescent

          3. Individuals in good health as determined by the outcome of medical history, physical
             examination, and clinical judgment of the investigator

          4. Individuals who can comply with study procedures and are available for follow-up

        Exclusion Criteria:

          1. Individuals with behavioral or cognitive impairment, including psychiatric illness, as
             determined by the investigator's clinical judgement may interfere with the subject's
             ability to participate in study

          2. Individuals with any progressive or severe neurologic disorder, seizure disorder or
             recent history of Guillian-Barré syndrome

          3. Individuals or (for children and adolescents) parents or legal guardians who are not
             able to comprehend and to follow all required study procedures for the whole period of
             the study

          4. Individuals with a history of illness/with an ongoing illness that, in the opinion of
             the investigator, may pose additional risk to the subject if he/she participates in
             the study

          5. Individuals who have a suspected/confirmed diagnosis for any Adverse event of Special
             interest

          6. Individuals with known or suspected impairment of the immune system including, but not
             limited to:

               -  autoimmune disease such as rheumatoid arthritis, HIV infection, hypo- or
                  agammaglobulinemia;

               -  autoimmune disorders;

               -  Systemic therapy with corticosteroids or other immunosuppressive therapy.

               -  Receipt of immunoglobulin preparation, blood products, and/or plasma derivatives
                  within 3 months prior to Day 1 or planned during the full length of the study

          7. Individuals who are pregnant or breastfeeding. Female subjects of childbearing
             potential must have a negative pregnancy test prior to study vaccines being
             administered

          8. If female, &quot;of childbearing potential&quot;, sexually active, and has not used any of the
             &quot;acceptable contraceptive methods&quot; for at least 2 months prior to study entry

          9. &quot;Of childbearing potential&quot; is defined as status post onset of menarche and not
             meeting any of the following conditions: menopausal for at least 2 years, status after
             bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy, or
             status after hysterectomy

         10. Acceptable birth control methods are defined as one or more of the following:

               1. Hormonal contraceptive (such as oral, injection, transdermal patch, implant,
                  cervical ring);

               2. Barrier (condom with spermicide or diaphragm with spermicide) each and every time
                  during intercourse;

               3. Intrauterine device (IUD);

               4. Monogamous relationship with vasectomized partner. Partner must have been
                  vasectomized for at least six months prior to the subject's study entry.

         11. If female of childbearing potential and sexually active, refusal to use an &quot;acceptable
             contraceptive method&quot; through to 3 weeks after last study vaccination

         12. Individuals who are allergic to any of the vaccine components.

         13. For children 17 years of age and younger: Individuals who have had ever a malignancy

         14. For adults 18 years or older: Individuals who have had a malignancy (excluding
             nonmelanotic skin cancer) or lymphoproliferative disorder within the past 5 years

         15. Individuals participating in any clinical trial with another investigational product
             30 days prior to first study visit or intent to participate in another clinical study
             at any time during the conduct of this study

         16. Individuals with a body temperature &gt;38°C (&gt;100.4°F) or any acute illness within 3
             days of intended study vaccination

         17. Individuals who have had a previous confirmed or suspected illness from swine flu
             (H3N2v)

         18. Individuals who have received any prior H3N2v vaccine

         19. Individuals who have received any other type of influenza vaccination (e.g.,
             &quot;seasonal&quot;) within 14 days prior to enrolment, or who plans to receive influenza
             vaccine during the treatment phase of this study (seasonal influenza vaccination is
             allowed after Day 43/Visit 3)

         20. Individuals who received any other licensed vaccines within 2 weeks (for inactivated
             vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study or who are
             planning to receive any (non-influenza) vaccine within 4 weeks from the study vaccines

         21. Individuals who are research staff involved with the clinical study or
             family/household members of research staff

         22. Individuals with a BMI &gt; 35 kg/m2 (adults), &gt; 29 kg/m2 (adolescents), or &gt; 21 kg/m2
             (children)

         23. Individuals with a history of drug or alcohol abuse within the past 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>92 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>51, Northern California Clinical Research Center</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>47, Benchmark Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>46, Johnson County Clinical Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49, Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>43, Central Kentucky Research Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>41, Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>44, Rochester Clinical Research Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>50, PMG Research of Raleigh</name>
      <address>
        <city>Raleight</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>45, Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>42, Research Acros</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>48, &quot;J. Lewis Research, Inc.</name>
      <address>
        <city>Salt lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <results_first_submitted>September 17, 2015</results_first_submitted>
  <results_first_submitted_qc>January 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2016</results_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 11 study centres in USA.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
          <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="P2">
          <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
          <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="P3">
          <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
          <description>Subjects 3 to &lt;9 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
        <group group_id="P4">
          <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
          <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="P5">
          <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
          <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="P6">
          <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
          <description>Subjects 9 to &lt;18 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
        <group group_id="P7">
          <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;65 YEARS</title>
          <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="P8">
          <title>A/H3N2C + MF59 Age Group: 18 TO &lt;65 YEARS</title>
          <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="P9">
          <title>A/H3N2C Age Group: 18 TO &lt;65 YEARS</title>
          <description>Subjects 18 to &lt;65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
        <group group_id="P10">
          <title>A/H3N2C + 1/2 MF59 Age Group: ≥65 YEARS</title>
          <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="P11">
          <title>A/H3N2C + MF59 Age Group: ≥65 YEARS</title>
          <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="P12">
          <title>A/H3N2C Age Group: ≥65 YEARS</title>
          <description>Subjects ≥65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="51"/>
                <participants group_id="P6" count="53"/>
                <participants group_id="P7" count="53"/>
                <participants group_id="P8" count="55"/>
                <participants group_id="P9" count="48"/>
                <participants group_id="P10" count="51"/>
                <participants group_id="P11" count="51"/>
                <participants group_id="P12" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="43"/>
                <participants group_id="P8" count="47"/>
                <participants group_id="P9" count="46"/>
                <participants group_id="P10" count="49"/>
                <participants group_id="P11" count="46"/>
                <participants group_id="P12" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other - Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis was done on all enrolled set.</population>
      <group_list>
        <group group_id="B1">
          <title>A/H3N2C + 1/2 MF59 : 3 TO &lt;9 YEARS</title>
          <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="B2">
          <title>A/H3N2C + MF59 : 3 TO &lt;9 YEARS</title>
          <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="B3">
          <title>A/H3N2C : 3 TO &lt;9 YEARS</title>
          <description>Subjects 3 to &lt;9 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
        <group group_id="B4">
          <title>A/H3N2C + 1/2 MF59 : 9 TO &lt;18 YEARS</title>
          <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="B5">
          <title>A/H3N2C + MF59 : 9 TO &lt;18 YEARS</title>
          <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="B6">
          <title>A/H3N2C : 9 TO &lt;18 YEARS</title>
          <description>Subjects 9 to &lt;18 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
        <group group_id="B7">
          <title>A/H3N2C + 1/2 MF59 : 18 TO &lt;65 YEARS</title>
          <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="B8">
          <title>A/H3N2C + MF59 : 18 TO &lt;65 YEARS</title>
          <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="B9">
          <title>A/H3N2C : 18 TO &lt;65 YEARS</title>
          <description>Subjects 18 to &lt;65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
        <group group_id="B10">
          <title>A/H3N2C + 1/2 MF59 : ≥65 YEARS</title>
          <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="B11">
          <title>A/H3N2C + MF59 : ≥65 YEARS</title>
          <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="B12">
          <title>A/H3N2C : ≥65 YEARS</title>
          <description>Subjects ≥65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="53"/>
            <count group_id="B5" value="51"/>
            <count group_id="B6" value="53"/>
            <count group_id="B7" value="53"/>
            <count group_id="B8" value="55"/>
            <count group_id="B9" value="48"/>
            <count group_id="B10" value="51"/>
            <count group_id="B11" value="51"/>
            <count group_id="B12" value="52"/>
            <count group_id="B13" value="627"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>YEARS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" spread="1.7"/>
                    <measurement group_id="B2" value="6" spread="1.6"/>
                    <measurement group_id="B3" value="6.2" spread="1.6"/>
                    <measurement group_id="B4" value="12.6" spread="2.7"/>
                    <measurement group_id="B5" value="12.8" spread="2.4"/>
                    <measurement group_id="B6" value="12.3" spread="2.4"/>
                    <measurement group_id="B7" value="42.3" spread="12.8"/>
                    <measurement group_id="B8" value="42.4" spread="13.3"/>
                    <measurement group_id="B9" value="44" spread="14.9"/>
                    <measurement group_id="B10" value="71.3" spread="5.3"/>
                    <measurement group_id="B11" value="72.9" spread="6.1"/>
                    <measurement group_id="B12" value="73.8" spread="6.1"/>
                    <measurement group_id="B13" value="33.2" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="32"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="28"/>
                    <measurement group_id="B10" value="31"/>
                    <measurement group_id="B11" value="25"/>
                    <measurement group_id="B12" value="32"/>
                    <measurement group_id="B13" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="20"/>
                    <measurement group_id="B11" value="26"/>
                    <measurement group_id="B12" value="20"/>
                    <measurement group_id="B13" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects (3 to &lt;9 Years of Age) Reporting Solicited Adverse Events (AEs) Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (3 to &lt;9 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
        <time_frame>Day 1 through Day 7 after each vaccination</time_frame>
        <population>Analysis was done on Solicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 - Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects, 3 to &lt; 9 years old, received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 - Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects, 3 to &lt; 9 years old, received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C - Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects, 3 to &lt; 9 years old, received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (3 to &lt;9 Years of Age) Reporting Solicited Adverse Events (AEs) Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (3 to &lt;9 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
          <population>Analysis was done on Solicited Safety Set.</population>
          <units>Number of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANY- Vac. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY- Vac. 2 (N= 45,52,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INJECTION SITE REACTIONS- Vacc. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INJECTION SITE REACTIONS- Vacc. 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECCHYMOSIS (mm), &lt; 6y (T.II, 1st Vac.,N=14,20,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECCHYMOSIS (mm), &lt; 6y (T.II, 2nd Vac.,N=11,21,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECCHYMOSIS (mm), ≥ 6y (T.II, 1st Vac.,N=33,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECCHYMOSIS (mm), ≥ 6y (T.II, 2nd Vac.,N=32,31,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERYTHEMA (mm), &lt; 6y (T.II, 1st Vac.,N=14,20,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERYTHEMA (mm), ≥ 6y (T.II, 1st Vac.,N=33,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERYTHEMA (mm), &lt; 6y (T.II, 2nd Vac.,N=12,21,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERYTHEMA (mm), ≥ 6y (T.II, 2nd Vac.,N=31,31,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDURATION (mm), &lt; 6y (T.II, 1st Vac.,N=14,20,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDURATION (mm), &lt; 6y (T.II, 2nd Vac.,N=12,21,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDURATION (mm), ≥ 6y (T.II, 1st Vac.,N=33,29,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDURATION (mm), ≥ 6y (T.II, 2nd Vac.,N=32,31,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYSTEMIC REACTIONS- Vacc. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYSTEMIC REACTIONS- Vacc. 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARTHRALGIA (1st Vac.,N=31,27,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARTHRALGIA (2nd Vac.,N=33,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BODY TEMPERATURE ≥38°C (1st Vac.,N=49,53,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BODY TEMPERATURE ≥38°C (2nd Vac.,N=42,52,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHANGE IN EATING HABITS (1st Vac.,N=13,19,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHANGE IN EATING HABITS (2nd Vac.,N=12,20,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIARRHEA (1st Vac.,N=45,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIARRHEA (2nd Vac.,N=43,50,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FATIGUE (1st Vac.,N=31,28,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FATIGUE (2nd Vac.,N=33,30,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEADACHE (1st Vac.,N=32,28,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEADACHE (2nd Vac.,N=33,31,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IRRITABILITY (1st Vac.,N=13,19,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IRRITABILITY (2nd Vac.,N=11,20,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOSS OF APPETITE (1st Vac.,N=32,27,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOSS OF APPETITE (2nd Vac.,N=32,30,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAISE (1st Vac.,N=32,28,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAISE (2nd Vac.,N=32,30,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYALGIA (1st Vac.,N=32,28,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYALGIA (2nd Vac.,N=33,31,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAUSEA (1st Vac.,N=32,28,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAUSEA (2nd Vac.,N=31,31,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PREV.OF PAIN/FEVER (1st Vac.,N=46,48,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PREV.OF PAIN/FEVER (2nd Vac.,N=44,51,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLEEPINESS (1st Vac.,N=13,19,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLEEPINESS (2nd Vac.,N=12,20,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TREAT.OF PAIN/FEVER (1st Vac.,N=46,49,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TREAT.OF PAIN/FEVER (2nd Vac.,N=44,51,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VOMITING (1st Vac.,N=46,47,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VOMITING (2nd Vac.,N=44,51,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects (9 to &lt;18 Years of Age) Reporting Solicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (9 to &lt;18 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
        <time_frame>Day 1 through Day 7 after each vaccination</time_frame>
        <population>Analysis was done on Solicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 - Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59 Subjects 3 to &lt;9 years.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 - Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C - Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (9 to &lt;18 Years of Age) Reporting Solicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (9 to &lt;18 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
          <population>Analysis was done on Solicited Safety Set.</population>
          <units>Number of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANY- Vac. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY- Vac. 2 (N=52,48,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INJECTION SITE REACTIONS- Vacc. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INJECTION SITE REACTIONS- Vacc. 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECCHYMOSIS (mm), ≥ 6y (T.II, 1st Vac.,N=53,51,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECCHYMOSIS (mm), ≥ 6y (T.II) (2nd Vac.,N=52,48,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERYTHEMA (mm), ≥ 6y (T.II) (1st Vac.,N=52,51,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERYTHEMA (mm), ≥ 6y (T.II) (2nd Vac.,N=51,48,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDURATION (mm), ≥ 6y (T.II) (1st Vac.,N=52,51,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDURATION (mm), ≥ 6y (T.II) (2nd Vac.,N=52,48,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYSTEMIC REACTIONS- Vacc. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYSTEMIC REACTIONS- Vacc. 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARTHRALGIA (1st Vac.,N=51,50,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARTHRALGIA (2nd Vac.,N=49,48,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BODY TEMPERATURE &gt;=38C (1st Vac.,N=53,51,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BODY TEMPERATURE ≥38°C (2nd Vac.,N=51,48,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIARRHEA (1st Vac.,N=51,51,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIARRHEA (2nd Vac.,N=50,47,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FATIGUE (1st Vac.,N=53,51,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FATIGUE (2nd Vac.,N=51,48,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEADACHE (1st Vac.,N=53,50,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEADACHE (2nd Vac.,N=50,48,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOSS OF APPETITE (1st Vac.,N=53,51,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOSS OF APPETITE (2nd Vac.,N=51,48,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAISE (1st Vac.,N=53,51,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAISE (2nd Vac.,N=51,48,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYALGIA (1st Vac.,N=52,51,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYALGIA (2nd Vac.,N=50,48,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAUSEA (1st Vac.,N=53,51,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAUSEA (2nd Vac.,N=50,48,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PREV.OF PAIN/FEVER (1st Vac.,N=54,49,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PREV.OF PAIN/FEVER (2nd Vac.,N=50,47,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TREAT.OF PAIN/FEVER (1st Vac.,N=54,50,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TREAT.OF PAIN/FEVER (2nd Vac.,N=49,47,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VOMITING (1st Vac.,N=53,51,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VOMITING (2nd Vac.,N=50,48,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects (18 to &lt; 65 Years) Reporting Solicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (18 to &lt; 65 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
        <time_frame>Day 1 through Day 7 after each vaccination</time_frame>
        <population>Analysis was done on Solicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 - Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 - Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C - Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old Received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (18 to &lt; 65 Years) Reporting Solicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (18 to &lt; 65 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
          <population>Analysis was done on Solicited Safety Set.</population>
          <units>Number of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANY- Vac. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY- Vac. 2 (N=47,51,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INJECTION SITE REACTIONS- Vacc. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INJECTION SITE REACTIONS- Vacc. 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECCHYMOSIS (mm), ≥ 6y (T.II, 1st Vac.,N=50,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECCHYMOSIS (mm), ≥ 6y (T.II, 2nd Vac.,N=46,51,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERYTHEMA (mm), ≥ 6y (T.II, 1st Vac.,N=50,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERYTHEMA (mm), ≥ 6y (T.II, 2nd Vac.,N=46,50,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDURATION (mm), ≥ 6y (T.II, 1st Vac.,N=50,53,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDURATION (mm), ≥ 6y (T.II, 2nd Vac.,N=46,51,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYSTEMIC REACTIONS- Vacc. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYSTEMIC REACTIONS- Vacc. 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARTHRALGIA (1st Vac.,N=50,51,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARTHRALGIA (2nd Vac.,N=46,48,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BODY TEMPERATURE ≥38°C (1st Vac.,N=51,54,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BODY TEMPERATURE ≥38°C (2nd Vac.,N=47,50,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIARRHEA (1st Vac.,N=49,52,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIARRHEA (2nd Vac.,N=44,50,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FATIGUE (1st Vac.,N=50,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FATIGUE (2nd Vac.,N=45,48,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEADACHE (1st Vac.,N=51,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEADACHE (2nd Vac.,N=47,49,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOSS OF APPETITE (1st Vac.,N=50,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOSS OF APPETITE (2nd Vac.,N=46,50,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAISE (1st Vac.,N=49,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAISE (2nd Vac.,N=45,50,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYALGIA (1st Vac.,N=51,51,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYALGIA (2nd Vac.,N=47,48,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAUSEA (1st Vac.,N=50,52,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAUSEA (2nd Vac.,N=47,50,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PREV.OF PAIN/FEVER (1st Vac.,N=49,52,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PREV.OF PAIN/FEVER (2nd Vac.,N=46,50,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TREAT.OF PAIN/FEVER (1st Vac.,N=49,53,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TREAT.OF PAIN /FEVER (2nd Vac.,N=46,50,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VOMITING (1st Vac.,N=49,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VOMITING (2nd Vac.,N=46,50,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects (≥ 65 Years) Reporting Solicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (≥ 65 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
        <time_frame>Day 1 through Day 7 after each vaccination</time_frame>
        <population>Analysis was done on Solicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 - Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 - Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C - Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old Received two injections of cell-culture derived H3N2c vaccine, each dose containing 15 µg H3N2c antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (≥ 65 Years) Reporting Solicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (≥ 65 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.</description>
          <population>Analysis was done on Solicited Safety Set.</population>
          <units>Number of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANY- Vac. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY- Vac. 2 (N=51,45,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INJECTION SITE REACTIONS- Vac. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INJECTION SITE REACTIONS- Vac. 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECCHYMOSIS (mm), ≥ 6y (T.II, 1st Vac.,N=51,49,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECCHYMOSIS (mm), ≥ 6y (T.II, 2nd Vac.,N=49,45,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERYTHEMA (mm), ≥ 6y (T.II, 1st Vac.,N=51,45,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERYTHEMA (mm), ≥ 6y (T.II, 2nd Vac.,N=49,44,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDURATION (mm), ≥ 6y (T.II, 1st Vac.,N=51,48,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDURATION (mm), ≥ 6y (T.II, 2nd Vac.,N=49,44,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYSTEMIC REACTIONS- Vacc. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYSTEMIC REACTIONS- Vacc. 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARTHRALGIA (1st Vac.,N=47,45,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARTHRALGIA (2nd Vac.,N=50,43,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BODY TEMPERATURE ≥38°C (1st Vac.,N=51,48,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BODY TEMPERATURE ≥38°C (2nd Vac.,N=51,44,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIARRHEA (1st Vac.,N=50,47,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIARRHEA (2nd Vac.,N=49,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FATIGUE (1st Vac.,N=49,48,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FATIGUE (2nd Vac.,N=51,44,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEADACHE (1st Vac.,N=50,49,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEADACHE (2nd Vac.,N=51,44,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOSS OF APPETITE (1st Vac.,N=50,48,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOSS OF APPETITE (2nd Vac.,N=50,45,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAISE (1st Vac.,N=50,48,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAISE (2nd Vac.,N=50,45,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYALGIA (1st Vac.,N=49,48,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYALGIA (2nd Vac.,N=50,43,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAUSEA (1st Vac.,N=51,49,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAUSEA (2nd Vac.,N=50,45,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PREV.OF PAIN/FEVER (1st Vac.,N=48,46,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PREV.OF PAIN/FEVER (2nd Vac.,N=50,44,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TREAT.OF PAIN/FEVER (1st Vac.,N=48,46,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TREAT.OF PAIN/FEVER (2nd Vac.,N=50,44,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VOMITING (1st Vac.,N=51,48,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VOMITING (2nd Vac.,N=49,45,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects (3 to ≥ 65 Years of Age) Reporting Unsolicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>The number of subjects reporting any unsolicited adverse events (AEs) from day 1 through day 21 after last vaccination within each vaccine group are reported.
The number of subjects reporting any serious adverse events (SAEs), AEs leading to withdrawal from the study, medically attended AEs, AE of special interest (AESI), new onset chronic disease (NOCDs) from day 1 through day 366, after receiving with H3N2 monovalent vaccine are reported.</description>
        <time_frame>Day 1 through Day 366</time_frame>
        <population>Analysis was done on unsolicited safety dataset i.e. all subjects in the exposed population who have post-vaccination unsolicited adverse event records.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O4">
            <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O5">
            <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O6">
            <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O7">
            <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O8">
            <title>A/H3N2C + MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O9">
            <title>A/H3N2C Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O10">
            <title>A/H3N2C + 1/2 MF59 Age Group: &gt;=65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O11">
            <title>A/H3N2C + MF59 Age Group: &gt;=65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O12">
            <title>A/H3N2C Age Group: &gt;=65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (3 to ≥ 65 Years of Age) Reporting Unsolicited Adverse Events Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>The number of subjects reporting any unsolicited adverse events (AEs) from day 1 through day 21 after last vaccination within each vaccine group are reported.
The number of subjects reporting any serious adverse events (SAEs), AEs leading to withdrawal from the study, medically attended AEs, AE of special interest (AESI), new onset chronic disease (NOCDs) from day 1 through day 366, after receiving with H3N2 monovalent vaccine are reported.</description>
          <population>Analysis was done on unsolicited safety dataset i.e. all subjects in the exposed population who have post-vaccination unsolicited adverse event records.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="54"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="52"/>
                <count group_id="O11" value="49"/>
                <count group_id="O12" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE (Day 1 to Day 366)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="31"/>
                    <measurement group_id="O11" value="22"/>
                    <measurement group_id="O12" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects (3 to ≥ 65 Years of Age) With Seroconversion or Significant Increase in Hemagglutination Inhibition (HI) Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>The percentages of subjects (3 to ≥ 65 years of age) achieving seroconversion or significant increase in HI antibody titers against H3N2 homologous strain, three weeks after receiving first (Day 22) and second (Day 43) vaccination are reported.
Seroconversion is defined as HI titer ≥1:40 for subjects negative at baseline (HI titer &lt;1:10); or a minimum 4-fold increase in HI titer for subjects positive at baseline (HI titer ≥1:10) on Day 22 and Day 43.</description>
        <time_frame>Day 22, Day 43 post vaccination</time_frame>
        <population>Analysis was done on Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O4">
            <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O5">
            <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O6">
            <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O7">
            <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O8">
            <title>A/H3N2C + MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O9">
            <title>A/H3N2C Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O10">
            <title>A/H3N2C + 1/2 MF59 Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O11">
            <title>A/H3N2C + MF59 Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O12">
            <title>A/H3N2C Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (3 to ≥ 65 Years of Age) With Seroconversion or Significant Increase in Hemagglutination Inhibition (HI) Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>The percentages of subjects (3 to ≥ 65 years of age) achieving seroconversion or significant increase in HI antibody titers against H3N2 homologous strain, three weeks after receiving first (Day 22) and second (Day 43) vaccination are reported.
Seroconversion is defined as HI titer ≥1:40 for subjects negative at baseline (HI titer &lt;1:10); or a minimum 4-fold increase in HI titer for subjects positive at baseline (HI titer ≥1:10) on Day 22 and Day 43.</description>
          <population>Analysis was done on Full Analysis Set.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="52"/>
                <count group_id="O8" value="54"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="49"/>
                <count group_id="O11" value="49"/>
                <count group_id="O12" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (N=47,54,49,52,48,53,52,54,48,49,49,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="85.5" upper_limit="99.5"/>
                    <measurement group_id="O2" value="98" lower_limit="90.1" upper_limit="99.95"/>
                    <measurement group_id="O3" value="71" lower_limit="56.7" upper_limit="83.4"/>
                    <measurement group_id="O4" value="88" lower_limit="76.6" upper_limit="95.6"/>
                    <measurement group_id="O5" value="98" lower_limit="88.9" upper_limit="99.95"/>
                    <measurement group_id="O6" value="85" lower_limit="72.4" upper_limit="93.3"/>
                    <measurement group_id="O7" value="73" lower_limit="59" upper_limit="84.4"/>
                    <measurement group_id="O8" value="89" lower_limit="77.4" upper_limit="95.8"/>
                    <measurement group_id="O9" value="67" lower_limit="51.6" upper_limit="79.6"/>
                    <measurement group_id="O10" value="57" lower_limit="42.2" upper_limit="71.2"/>
                    <measurement group_id="O11" value="71" lower_limit="56.7" upper_limit="83.4"/>
                    <measurement group_id="O12" value="61" lower_limit="46.1" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43(N=43,53,48,52,49,53,51,52,48,48,49,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.3" upper_limit="100"/>
                    <measurement group_id="O3" value="92" lower_limit="80" upper_limit="97.7"/>
                    <measurement group_id="O4" value="94" lower_limit="84.1" upper_limit="98.8"/>
                    <measurement group_id="O5" value="98" lower_limit="89.1" upper_limit="99.95"/>
                    <measurement group_id="O6" value="91" lower_limit="79.3" upper_limit="96.9"/>
                    <measurement group_id="O7" value="82" lower_limit="69.1" upper_limit="91.6"/>
                    <measurement group_id="O8" value="92" lower_limit="81.5" upper_limit="97.9"/>
                    <measurement group_id="O9" value="71" lower_limit="55.9" upper_limit="83"/>
                    <measurement group_id="O10" value="58" lower_limit="43.2" upper_limit="72.4"/>
                    <measurement group_id="O11" value="80" lower_limit="65.7" upper_limit="89.8"/>
                    <measurement group_id="O12" value="64" lower_limit="49.2" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean HI Antibody Titers (GMTs) Following Vaccination With H3N2 Monovalent Vaccine (3 to ≥ 65 Years of Age).</title>
        <description>The HI antibody titers against H3N2 homologous strain at baseline (Day 1), three weeks after first (Day 22) and second (Day 43) vaccination and persisting titers at six months (Day 183) and one year (Day 366) after vaccination are reported in terms of GMTs is reported across subjects with age groups 3 to ≥ 65 years.</description>
        <time_frame>Day 1, Day 22, Day 43, Day 183 and Day 366 post vaccination</time_frame>
        <population>Analysis was done on Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O4">
            <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O5">
            <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O6">
            <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O7">
            <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O8">
            <title>A/H3N2C + MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O9">
            <title>A/H3N2C Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O10">
            <title>A/H3N2C + 1/2 MF59 Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O11">
            <title>A/H3N2C + MF59 Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O12">
            <title>A/H3N2C Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean HI Antibody Titers (GMTs) Following Vaccination With H3N2 Monovalent Vaccine (3 to ≥ 65 Years of Age).</title>
          <description>The HI antibody titers against H3N2 homologous strain at baseline (Day 1), three weeks after first (Day 22) and second (Day 43) vaccination and persisting titers at six months (Day 183) and one year (Day 366) after vaccination are reported in terms of GMTs is reported across subjects with age groups 3 to ≥ 65 years.</description>
          <population>Analysis was done on Full Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="53"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="50"/>
                <count group_id="O11" value="50"/>
                <count group_id="O12" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.48" lower_limit="6.89" upper_limit="10"/>
                    <measurement group_id="O2" value="8.26" lower_limit="6.74" upper_limit="10"/>
                    <measurement group_id="O3" value="8.8" lower_limit="7.10" upper_limit="11"/>
                    <measurement group_id="O4" value="28" lower_limit="21" upper_limit="37"/>
                    <measurement group_id="O5" value="29" lower_limit="22" upper_limit="39"/>
                    <measurement group_id="O6" value="27" lower_limit="20" upper_limit="35"/>
                    <measurement group_id="O7" value="34" lower_limit="26" upper_limit="44"/>
                    <measurement group_id="O8" value="52" lower_limit="40" upper_limit="68"/>
                    <measurement group_id="O9" value="42" lower_limit="32" upper_limit="56"/>
                    <measurement group_id="O10" value="36" lower_limit="28" upper_limit="47"/>
                    <measurement group_id="O11" value="32" lower_limit="25" upper_limit="42"/>
                    <measurement group_id="O12" value="26" lower_limit="20" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (N=47,54,49,52,48,53,52,54,48,49,49,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192" lower_limit="134" upper_limit="275"/>
                    <measurement group_id="O2" value="277" lower_limit="198" upper_limit="387"/>
                    <measurement group_id="O3" value="93" lower_limit="65" upper_limit="132"/>
                    <measurement group_id="O4" value="386" lower_limit="293" upper_limit="510"/>
                    <measurement group_id="O5" value="456" lower_limit="341" upper_limit="609"/>
                    <measurement group_id="O6" value="343" lower_limit="261" upper_limit="452"/>
                    <measurement group_id="O7" value="300" lower_limit="217" upper_limit="415"/>
                    <measurement group_id="O8" value="504" lower_limit="367" upper_limit="692"/>
                    <measurement group_id="O9" value="226" lower_limit="162" upper_limit="315"/>
                    <measurement group_id="O10" value="135" lower_limit="103" upper_limit="177"/>
                    <measurement group_id="O11" value="206" lower_limit="157" upper_limit="270"/>
                    <measurement group_id="O12" value="140" lower_limit="107" upper_limit="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=43,53,48,52,49,53,51,52,48,48,49,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524" lower_limit="396" upper_limit="694"/>
                    <measurement group_id="O2" value="679" lower_limit="527" upper_limit="874"/>
                    <measurement group_id="O3" value="198" lower_limit="152" upper_limit="258"/>
                    <measurement group_id="O4" value="486" lower_limit="379" upper_limit="623"/>
                    <measurement group_id="O5" value="656" lower_limit="508" upper_limit="849"/>
                    <measurement group_id="O6" value="389" lower_limit="304" upper_limit="498"/>
                    <measurement group_id="O7" value="276" lower_limit="208" upper_limit="365"/>
                    <measurement group_id="O8" value="427" lower_limit="324" upper_limit="564"/>
                    <measurement group_id="O9" value="261" lower_limit="196" upper_limit="347"/>
                    <measurement group_id="O10" value="131" lower_limit="102" upper_limit="170"/>
                    <measurement group_id="O11" value="202" lower_limit="157" upper_limit="261"/>
                    <measurement group_id="O12" value="163" lower_limit="126" upper_limit="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183 (N=39,44,42,47,50,47,45,50,46,47,48,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="75" upper_limit="126"/>
                    <measurement group_id="O2" value="145" lower_limit="113" upper_limit="185"/>
                    <measurement group_id="O3" value="67" lower_limit="52" upper_limit="86"/>
                    <measurement group_id="O4" value="173" lower_limit="137" upper_limit="218"/>
                    <measurement group_id="O5" value="242" lower_limit="194" upper_limit="302"/>
                    <measurement group_id="O6" value="170" lower_limit="135" upper_limit="214"/>
                    <measurement group_id="O7" value="161" lower_limit="120" upper_limit="217"/>
                    <measurement group_id="O8" value="219" lower_limit="166" upper_limit="289"/>
                    <measurement group_id="O9" value="188" lower_limit="142" upper_limit="251"/>
                    <measurement group_id="O10" value="93" lower_limit="72" upper_limit="121"/>
                    <measurement group_id="O11" value="122" lower_limit="94" upper_limit="157"/>
                    <measurement group_id="O12" value="98" lower_limit="76" upper_limit="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366 (N=38,43,38,47,50,47,43,47,46,48,46,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="35" upper_limit="61"/>
                    <measurement group_id="O2" value="70" lower_limit="53" upper_limit="91"/>
                    <measurement group_id="O3" value="37" lower_limit="28" upper_limit="49"/>
                    <measurement group_id="O4" value="112" lower_limit="86" upper_limit="148"/>
                    <measurement group_id="O5" value="124" lower_limit="96" upper_limit="161"/>
                    <measurement group_id="O6" value="111" lower_limit="84" upper_limit="145"/>
                    <measurement group_id="O7" value="111" lower_limit="84" upper_limit="148"/>
                    <measurement group_id="O8" value="170" lower_limit="130" upper_limit="223"/>
                    <measurement group_id="O9" value="126" lower_limit="96" upper_limit="165"/>
                    <measurement group_id="O10" value="55" lower_limit="43" upper_limit="69"/>
                    <measurement group_id="O11" value="71" lower_limit="56" upper_limit="91"/>
                    <measurement group_id="O12" value="68" lower_limit="53" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio of Subjects (3 to ≥ 65 Years of Age) Post Versus Pre-vaccination HI Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>The geometric mean ratio (GMR) of post versus pre-vaccination HI antibody titers against H3N2 homologous strain following vaccination as compared to baseline titers are reported for after first (Day 22/Day 1) and second (Day 43/Day 1) vaccination and for persisting titers at six months (Day 183/Day1) and one year (Day 366/Day 1) is reported across subjects with age groups 3 to ≥ 65 years.</description>
        <time_frame>Day 22/Day 1, Day 43/Day 1, Day 183/Day 1, Day 366/Day 1</time_frame>
        <population>Analysis was done on Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O4">
            <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O5">
            <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O6">
            <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O7">
            <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O8">
            <title>A/H3N2C + MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O9">
            <title>A/H3N2C Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O10">
            <title>A/H3N2C + 1/2 MF59 Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O11">
            <title>A/H3N2C + MF59 Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O12">
            <title>A/H3N2C Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio of Subjects (3 to ≥ 65 Years of Age) Post Versus Pre-vaccination HI Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>The geometric mean ratio (GMR) of post versus pre-vaccination HI antibody titers against H3N2 homologous strain following vaccination as compared to baseline titers are reported for after first (Day 22/Day 1) and second (Day 43/Day 1) vaccination and for persisting titers at six months (Day 183/Day1) and one year (Day 366/Day 1) is reported across subjects with age groups 3 to ≥ 65 years.</description>
          <population>Analysis was done on Full Analysis Set.</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="52"/>
                <count group_id="O8" value="54"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="49"/>
                <count group_id="O11" value="49"/>
                <count group_id="O12" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day22/Day1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="15" upper_limit="32"/>
                    <measurement group_id="O2" value="33" lower_limit="23" upper_limit="47"/>
                    <measurement group_id="O3" value="11" lower_limit="7.51" upper_limit="16"/>
                    <measurement group_id="O4" value="14" lower_limit="9.58" upper_limit="19"/>
                    <measurement group_id="O5" value="15" lower_limit="10" upper_limit="22"/>
                    <measurement group_id="O6" value="13" lower_limit="8.91" upper_limit="18"/>
                    <measurement group_id="O7" value="7.54" lower_limit="5.41" upper_limit="11"/>
                    <measurement group_id="O8" value="11" lower_limit="8.16" upper_limit="16"/>
                    <measurement group_id="O9" value="5.35" lower_limit="3.80" upper_limit="7.55"/>
                    <measurement group_id="O10" value="3.79" lower_limit="2.71" upper_limit="5.29"/>
                    <measurement group_id="O11" value="6.64" lower_limit="4.75" upper_limit="9.28"/>
                    <measurement group_id="O12" value="5.13" lower_limit="3.70" upper_limit="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day43/Day1 (N=43,53,48,52,49,53,51,52,48,48,49,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="43" upper_limit="81"/>
                    <measurement group_id="O2" value="82" lower_limit="62" upper_limit="109"/>
                    <measurement group_id="O3" value="23" lower_limit="17" upper_limit="31"/>
                    <measurement group_id="O4" value="18" lower_limit="13" upper_limit="25"/>
                    <measurement group_id="O5" value="21" lower_limit="15" upper_limit="30"/>
                    <measurement group_id="O6" value="14" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O7" value="7.16" lower_limit="5.34" upper_limit="9.61"/>
                    <measurement group_id="O8" value="9.58" lower_limit="7.17" upper_limit="13"/>
                    <measurement group_id="O9" value="6.24" lower_limit="4.62" upper_limit="8.44"/>
                    <measurement group_id="O10" value="3.82" lower_limit="2.80" upper_limit="5.21"/>
                    <measurement group_id="O11" value="6.55" lower_limit="4.81" upper_limit="8.91"/>
                    <measurement group_id="O12" value="5.94" lower_limit="4.38" upper_limit="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day183/Day1(N=39,44,42,47,50,47,45,50,46,47,48,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7.48" upper_limit="14"/>
                    <measurement group_id="O2" value="17" lower_limit="13" upper_limit="23"/>
                    <measurement group_id="O3" value="7.17" lower_limit="5.31" upper_limit="9.68"/>
                    <measurement group_id="O4" value="6.59" lower_limit="4.87" upper_limit="8.91"/>
                    <measurement group_id="O5" value="8.2" lower_limit="6.13" upper_limit="11"/>
                    <measurement group_id="O6" value="6.38" lower_limit="4.73" upper_limit="8.63"/>
                    <measurement group_id="O7" value="3.95" lower_limit="2.93" upper_limit="5.31"/>
                    <measurement group_id="O8" value="4.95" lower_limit="3.75" upper_limit="6.54"/>
                    <measurement group_id="O9" value="4.4" lower_limit="3.29" upper_limit="5.87"/>
                    <measurement group_id="O10" value="2.6" lower_limit="1.93" upper_limit="3.49"/>
                    <measurement group_id="O11" value="3.83" lower_limit="2.85" upper_limit="5.14"/>
                    <measurement group_id="O12" value="3.4" lower_limit="2.54" upper_limit="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day366/Day1(N=38,43,38,47,50,47,43,47,46,48,46,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" lower_limit="3.43" upper_limit="6.79"/>
                    <measurement group_id="O2" value="8.23" lower_limit="5.98" upper_limit="11"/>
                    <measurement group_id="O3" value="4.13" lower_limit="2.93" upper_limit="5.82"/>
                    <measurement group_id="O4" value="4.28" lower_limit="3.07" upper_limit="5.95"/>
                    <measurement group_id="O5" value="4.21" lower_limit="3.06" upper_limit="5.79"/>
                    <measurement group_id="O6" value="4.15" lower_limit="2.99" upper_limit="5.77"/>
                    <measurement group_id="O7" value="2.79" lower_limit="2.10" upper_limit="3.70"/>
                    <measurement group_id="O8" value="3.97" lower_limit="3.03" upper_limit="5.21"/>
                    <measurement group_id="O9" value="2.99" lower_limit="2.28" upper_limit="3.93"/>
                    <measurement group_id="O10" value="1.6" lower_limit="1.23" upper_limit="2.09"/>
                    <measurement group_id="O11" value="2.33" lower_limit="1.77" upper_limit="3.05"/>
                    <measurement group_id="O12" value="2.33" lower_limit="1.79" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (3 to ≥ 65 Years of Age) Achieving HI Titers ≥1:40 Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>The percentages of subjects (3 to ≥ 65 years of age) demonstrating HI titers ≥1:40 against H3N2 homologous strain on Day 183 and Day 366 post vaccination.</description>
        <time_frame>Day 183 and Day 366 post vaccination</time_frame>
        <population>Analysis was done on the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O4">
            <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O5">
            <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O6">
            <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O7">
            <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O8">
            <title>A/H3N2C + MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O9">
            <title>A/H3N2C Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O10">
            <title>A/H3N2C + 1/2 MF59 Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O11">
            <title>A/H3N2C + MF59 Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O12">
            <title>A/H3N2C Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (3 to ≥ 65 Years of Age) Achieving HI Titers ≥1:40 Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>The percentages of subjects (3 to ≥ 65 years of age) demonstrating HI titers ≥1:40 against H3N2 homologous strain on Day 183 and Day 366 post vaccination.</description>
          <population>Analysis was done on the full analysis set.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="50"/>
                <count group_id="O9" value="46"/>
                <count group_id="O10" value="48"/>
                <count group_id="O11" value="48"/>
                <count group_id="O12" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 183 (N=39,44,42,47,50,47,45,50,46,47,48,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="82.7" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98" lower_limit="88" upper_limit="99.94"/>
                    <measurement group_id="O3" value="81" lower_limit="65.9" upper_limit="91.4"/>
                    <measurement group_id="O4" value="98" lower_limit="88.7" upper_limit="99.95"/>
                    <measurement group_id="O5" value="100" lower_limit="92.9" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="92.5" upper_limit="100"/>
                    <measurement group_id="O7" value="87" lower_limit="73.2" upper_limit="94.9"/>
                    <measurement group_id="O8" value="100" lower_limit="92.9" upper_limit="100"/>
                    <measurement group_id="O9" value="87" lower_limit="73.7" upper_limit="95.1"/>
                    <measurement group_id="O10" value="91" lower_limit="79.6" upper_limit="97.6"/>
                    <measurement group_id="O11" value="94" lower_limit="82.8" upper_limit="98.7"/>
                    <measurement group_id="O12" value="88" lower_limit="75.2" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366 (N=38,43,38,47,50,47,43,47,46,48,46,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="65.7" upper_limit="92.3"/>
                    <measurement group_id="O2" value="91" lower_limit="77.9" upper_limit="97.4"/>
                    <measurement group_id="O3" value="58" lower_limit="40.8" upper_limit="73.7"/>
                    <measurement group_id="O4" value="94" lower_limit="82.5" upper_limit="98.7"/>
                    <measurement group_id="O5" value="98" lower_limit="89.4" upper_limit="99.95"/>
                    <measurement group_id="O6" value="89" lower_limit="76.9" upper_limit="96.5"/>
                    <measurement group_id="O7" value="81" lower_limit="66.6" upper_limit="91.6"/>
                    <measurement group_id="O8" value="96" lower_limit="85.5" upper_limit="99.5"/>
                    <measurement group_id="O9" value="80" lower_limit="66.1" upper_limit="90.6"/>
                    <measurement group_id="O10" value="75" lower_limit="60.4" upper_limit="86.4"/>
                    <measurement group_id="O11" value="80" lower_limit="66.1" upper_limit="90.6"/>
                    <measurement group_id="O12" value="80" lower_limit="65.7" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (3 to ≥ 61 Years of Age) With Seroconversion or Significant Increase in Hemagglutination Inhibition Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>The percentage of subjects achieving seroconversion or significant increase for HI antibody titers at three weeks after receiving first (Day 22) and second (Day 43) vaccination is reported, across age groups of 3 to ≥61 years.
Seroconversion is defined as HI titer ≥1:40 for subjects negative at baseline (HI titer &lt;1:10); or a minimum 4-fold increase in HI titer for subjects positive at baseline (HI titer ≥1:10) on Day 22 and Day 43.</description>
        <time_frame>Day 22, Day 43 post vaccination</time_frame>
        <population>Analysis was done on Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O4">
            <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O5">
            <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O6">
            <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O7">
            <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;61 YEARS</title>
            <description>Subjects 18 to &lt;61 years old Received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O8">
            <title>A/H3N2C + MF59 Age Group: 18 TO &lt;61 YEARS</title>
            <description>Subjects 18 to &lt;61 years old Received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O9">
            <title>A/H3N2C Age Group: 18 TO &lt;61 YEARS</title>
            <description>Subjects 18 to &lt;61 years old Received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O10">
            <title>A/H3N2C + 1/2 MF59 Age Group: ≥61 YEARS</title>
            <description>Subjects ≥61 years old Received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O11">
            <title>A/H3N2C + MF59 Age Group: ≥61 YEARS</title>
            <description>Subjects ≥61 years old Received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O12">
            <title>A/H3N2C Age Group: ≥61 YEARS</title>
            <description>Subjects ≥61 years old Received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (3 to ≥ 61 Years of Age) With Seroconversion or Significant Increase in Hemagglutination Inhibition Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>The percentage of subjects achieving seroconversion or significant increase for HI antibody titers at three weeks after receiving first (Day 22) and second (Day 43) vaccination is reported, across age groups of 3 to ≥61 years.
Seroconversion is defined as HI titer ≥1:40 for subjects negative at baseline (HI titer &lt;1:10); or a minimum 4-fold increase in HI titer for subjects positive at baseline (HI titer ≥1:10) on Day 22 and Day 43.</description>
          <population>Analysis was done on Full Analysis Set.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="39"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="55"/>
                <count group_id="O12" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="85.2" upper_limit="99.5"/>
                    <measurement group_id="O2" value="98" lower_limit="90.1" upper_limit="99.95"/>
                    <measurement group_id="O3" value="71" lower_limit="56.7" upper_limit="83.4"/>
                    <measurement group_id="O4" value="89" lower_limit="77" upper_limit="95.7"/>
                    <measurement group_id="O5" value="98" lower_limit="88.9" upper_limit="99.95"/>
                    <measurement group_id="O6" value="85" lower_limit="72.4" upper_limit="93.3"/>
                    <measurement group_id="O7" value="74" lower_limit="59.7" upper_limit="86.1"/>
                    <measurement group_id="O8" value="90" lower_limit="77.3" upper_limit="96.5"/>
                    <measurement group_id="O9" value="64" lower_limit="47.2" upper_limit="78.8"/>
                    <measurement group_id="O10" value="57" lower_limit="43.2" upper_limit="70.8"/>
                    <measurement group_id="O11" value="73" lower_limit="59" upper_limit="83.9"/>
                    <measurement group_id="O12" value="63" lower_limit="49.9" upper_limit="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43(N=43,53,48,52,49,53,46,46,39,53,55,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.3" upper_limit="100"/>
                    <measurement group_id="O3" value="92" lower_limit="80" upper_limit="97.7"/>
                    <measurement group_id="O4" value="94" lower_limit="84.1" upper_limit="98.8"/>
                    <measurement group_id="O5" value="98" lower_limit="89.1" upper_limit="99.95"/>
                    <measurement group_id="O6" value="91" lower_limit="79.3" upper_limit="96.9"/>
                    <measurement group_id="O7" value="85" lower_limit="71.1" upper_limit="93.7"/>
                    <measurement group_id="O8" value="93" lower_limit="82.1" upper_limit="98.6"/>
                    <measurement group_id="O9" value="67" lower_limit="49.8" upper_limit="80.9"/>
                    <measurement group_id="O10" value="58" lower_limit="44.1" upper_limit="71.9"/>
                    <measurement group_id="O11" value="80" lower_limit="67" upper_limit="89.6"/>
                    <measurement group_id="O12" value="68" lower_limit="54.4" upper_limit="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (3 to ≥ 61 Years of Age) Achieving HI Titers ≥1:40 Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>The percentages of subjects achieving HI titers ≥1:40 against H3N2 homologous strain at three weeks after receiving first (day 22) and second (day 43) vaccination, is reported across age groups of 3 to ≥ 61 years.</description>
        <time_frame>Day 1, Day 22, Day 43 post vaccination</time_frame>
        <population>Analysis was done on Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O4">
            <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O5">
            <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O6">
            <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O7">
            <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;61 YEARS</title>
            <description>Subjects 18 to &lt;61years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O8">
            <title>A/H3N2C + MF59 Age Group: 18 TO &lt;61 YEARS</title>
            <description>Subjects 18 to &lt;61 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O9">
            <title>A/H3N2C Age Group: 18 TO &lt;61 YEARS</title>
            <description>Subjects 18 to &lt;61years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O10">
            <title>A/H3N2C + 1/2 MF59 Age Group: ≥61 YEARS</title>
            <description>Subjects ≥61 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O11">
            <title>A/H3N2C + MF59 Age Group: ≥61 YEARS</title>
            <description>Subjects ≥61 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O12">
            <title>A/H3N2C Age Group: ≥61 YEARS</title>
            <description>Subjects ≥61 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (3 to ≥ 61 Years of Age) Achieving HI Titers ≥1:40 Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>The percentages of subjects achieving HI titers ≥1:40 against H3N2 homologous strain at three weeks after receiving first (day 22) and second (day 43) vaccination, is reported across age groups of 3 to ≥ 61 years.</description>
          <population>Analysis was done on Full Analysis Set.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="49"/>
                <count group_id="O9" value="39"/>
                <count group_id="O10" value="55"/>
                <count group_id="O11" value="56"/>
                <count group_id="O12" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="2.1" upper_limit="18.5"/>
                    <measurement group_id="O2" value="7" lower_limit="2" upper_limit="17.6"/>
                    <measurement group_id="O3" value="14" lower_limit="5.8" upper_limit="26.7"/>
                    <measurement group_id="O4" value="44" lower_limit="30.9" upper_limit="58.6"/>
                    <measurement group_id="O5" value="59" lower_limit="44.2" upper_limit="72.4"/>
                    <measurement group_id="O6" value="49" lower_limit="35.1" upper_limit="63.2"/>
                    <measurement group_id="O7" value="60" lower_limit="45.3" upper_limit="74.2"/>
                    <measurement group_id="O8" value="67" lower_limit="52.5" upper_limit="80.1"/>
                    <measurement group_id="O9" value="74" lower_limit="57.9" upper_limit="87"/>
                    <measurement group_id="O10" value="53" lower_limit="38.8" upper_limit="66.3"/>
                    <measurement group_id="O11" value="54" lower_limit="39.7" upper_limit="67"/>
                    <measurement group_id="O12" value="44" lower_limit="31.5" upper_limit="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22(N=46,54,49,53,48,53,47,48,39,54,55,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="85.2" upper_limit="99.5"/>
                    <measurement group_id="O2" value="98" lower_limit="90.1" upper_limit="99.95"/>
                    <measurement group_id="O3" value="78" lower_limit="63.4" upper_limit="88.2"/>
                    <measurement group_id="O4" value="100" lower_limit="93.3" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="92.6" upper_limit="100"/>
                    <measurement group_id="O6" value="98" lower_limit="89.9" upper_limit="99.95"/>
                    <measurement group_id="O7" value="98" lower_limit="88.7" upper_limit="99.95"/>
                    <measurement group_id="O8" value="100" lower_limit="92.6" upper_limit="100"/>
                    <measurement group_id="O9" value="90" lower_limit="75.8" upper_limit="97.1"/>
                    <measurement group_id="O10" value="93" lower_limit="82.1" upper_limit="97.9"/>
                    <measurement group_id="O11" value="100" lower_limit="93.5" upper_limit="100"/>
                    <measurement group_id="O12" value="93" lower_limit="83.8" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43(N=43,53,48,52,49,53,46,46,39,53,55,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.3" upper_limit="100"/>
                    <measurement group_id="O3" value="96" lower_limit="85.7" upper_limit="99.5"/>
                    <measurement group_id="O4" value="100" lower_limit="93.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="92.7" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="93.3" upper_limit="100"/>
                    <measurement group_id="O7" value="98" lower_limit="88.5" upper_limit="99.94"/>
                    <measurement group_id="O8" value="100" lower_limit="92.3" upper_limit="100"/>
                    <measurement group_id="O9" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O10" value="96" lower_limit="87" upper_limit="99.54"/>
                    <measurement group_id="O11" value="100" lower_limit="93.5" upper_limit="100"/>
                    <measurement group_id="O12" value="95" lower_limit="85.9" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects (3 to ≥ 65 Years of Age) Achieving HI Titers ≥1:40 Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>The percentages of subjects (3 to ≥ 65 years of age) achieving HI titers ≥1:40 against H3N2 homologous strain at baseline (Day 1) and three weeks after receiving first (Day 22) and second (Day 43) vaccination are reported.</description>
        <time_frame>Day 1, Day 22, Day 43 post vaccination</time_frame>
        <population>Analysis was done on Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O4">
            <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O5">
            <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O6">
            <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O7">
            <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O8">
            <title>A/H3N2C + MF59 Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O9">
            <title>A/H3N2C Age Group: 18 TO &lt;65 YEARS</title>
            <description>Subjects 18 to &lt;65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O10">
            <title>A/H3N2C + 1/2 MF59 Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O11">
            <title>A/H3N2C + MF59 Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O12">
            <title>A/H3N2C Age Group: ≥65 YEARS</title>
            <description>Subjects ≥65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (3 to ≥ 65 Years of Age) Achieving HI Titers ≥1:40 Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>The percentages of subjects (3 to ≥ 65 years of age) achieving HI titers ≥1:40 against H3N2 homologous strain at baseline (Day 1) and three weeks after receiving first (Day 22) and second (Day 43) vaccination are reported.</description>
          <population>Analysis was done on Full Analysis Set.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="53"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="50"/>
                <count group_id="O11" value="50"/>
                <count group_id="O12" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="2.1" upper_limit="18.2"/>
                    <measurement group_id="O2" value="7" lower_limit="2" upper_limit="17.6"/>
                    <measurement group_id="O3" value="14" lower_limit="5.8" upper_limit="26.7"/>
                    <measurement group_id="O4" value="45" lower_limit="31.6" upper_limit="59.6"/>
                    <measurement group_id="O5" value="59" lower_limit="44.2" upper_limit="72.4"/>
                    <measurement group_id="O6" value="49" lower_limit="35.1" upper_limit="63.2"/>
                    <measurement group_id="O7" value="57" lower_limit="42.3" upper_limit="70.2"/>
                    <measurement group_id="O8" value="67" lower_limit="53.3" upper_limit="79.3"/>
                    <measurement group_id="O9" value="67" lower_limit="51.6" upper_limit="79.6"/>
                    <measurement group_id="O10" value="56" lower_limit="41.3" upper_limit="70"/>
                    <measurement group_id="O11" value="52" lower_limit="37.4" upper_limit="66.3"/>
                    <measurement group_id="O12" value="46" lower_limit="32.2" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (N=47,54,49,52,48,53,52,54,48,49,49,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="85.5" upper_limit="99.5"/>
                    <measurement group_id="O2" value="98" lower_limit="90.1" upper_limit="99.95"/>
                    <measurement group_id="O3" value="78" lower_limit="63.4" upper_limit="88.2"/>
                    <measurement group_id="O4" value="100" lower_limit="93.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="92.6" upper_limit="100"/>
                    <measurement group_id="O6" value="98" lower_limit="89.9" upper_limit="99.95"/>
                    <measurement group_id="O7" value="96" lower_limit="86.8" upper_limit="99.53"/>
                    <measurement group_id="O8" value="100" lower_limit="93.4" upper_limit="100"/>
                    <measurement group_id="O9" value="88" lower_limit="74.8" upper_limit="95.3"/>
                    <measurement group_id="O10" value="94" lower_limit="83.1" upper_limit="98.7"/>
                    <measurement group_id="O11" value="100" lower_limit="92.7" upper_limit="100"/>
                    <measurement group_id="O12" value="96" lower_limit="86.5" upper_limit="99.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=43,53,48,52,49,53,51,52,48,48,49,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.3" upper_limit="100"/>
                    <measurement group_id="O3" value="96" lower_limit="85.7" upper_limit="99.5"/>
                    <measurement group_id="O4" value="100" lower_limit="93.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="92.7" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="93.3" upper_limit="100"/>
                    <measurement group_id="O7" value="96" lower_limit="86.5" upper_limit="99.52"/>
                    <measurement group_id="O8" value="100" lower_limit="93.2" upper_limit="100"/>
                    <measurement group_id="O9" value="98" lower_limit="88.9" upper_limit="99.95"/>
                    <measurement group_id="O10" value="98" lower_limit="88.9" upper_limit="99.95"/>
                    <measurement group_id="O11" value="100" lower_limit="92.7" upper_limit="100"/>
                    <measurement group_id="O12" value="96" lower_limit="86.3" upper_limit="99.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMR in Subjects (3 to ≥ 61 Years of Age) of Post-vaccination Versus Pre-vaccination HI Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</title>
        <description>GMR of post-vaccination versus pre-vaccination HI GMTs following vaccination with H3N2 monovalent vaccine is reported across subjects with age groups 3 to ≥ 61 years.</description>
        <time_frame>Day 22/Day 1, Day 43/Day 1, Day183/ Day 1, Day 366/Day 1</time_frame>
        <population>Analysis was done on Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O2">
            <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O3">
            <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
            <description>Subjects 3 to &lt;9 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O4">
            <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O5">
            <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O6">
            <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
            <description>Subjects 9 to &lt;18 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O7">
            <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;61 YEARS</title>
            <description>Subjects 18 to &lt;61 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O8">
            <title>A/H3N2C + MF59 Age Group: 18 TO &lt;61 YEARS</title>
            <description>Subjects 18 to &lt;61 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O9">
            <title>A/H3N2C Age Group: 18 TO &lt;61 YEARS</title>
            <description>Subjects 18 to &lt;61 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
          <group group_id="O10">
            <title>A/H3N2C + 1/2 MF59 Age Group: ≥61 YEARS</title>
            <description>Subjects ≥61 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75 µg antigen adjuvanted with half dose MF59.</description>
          </group>
          <group group_id="O11">
            <title>A/H3N2C + MF59 Age Group: ≥61 YEARS</title>
            <description>Subjects ≥61 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
          </group>
          <group group_id="O12">
            <title>A/H3N2C Age Group: ≥61 YEARS</title>
            <description>Subjects ≥61 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
          </group>
        </group_list>
        <measure>
          <title>GMR in Subjects (3 to ≥ 61 Years of Age) of Post-vaccination Versus Pre-vaccination HI Antibody Titers Following Vaccination With H3N2 Monovalent Vaccine.</title>
          <description>GMR of post-vaccination versus pre-vaccination HI GMTs following vaccination with H3N2 monovalent vaccine is reported across subjects with age groups 3 to ≥ 61 years.</description>
          <population>Analysis was done on Full Analysis Set.</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="39"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="55"/>
                <count group_id="O12" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day22/Day1(N=46,54,49,53,48,53,47,48,39,54,55,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="15" upper_limit="32"/>
                    <measurement group_id="O2" value="33" lower_limit="23" upper_limit="47"/>
                    <measurement group_id="O3" value="11" lower_limit="7.50" upper_limit="16"/>
                    <measurement group_id="O4" value="14" lower_limit="9.76" upper_limit="19"/>
                    <measurement group_id="O5" value="15" lower_limit="10" upper_limit="22"/>
                    <measurement group_id="O6" value="13" lower_limit="8.91" upper_limit="18"/>
                    <measurement group_id="O7" value="7.8" lower_limit="5.48" upper_limit="11"/>
                    <measurement group_id="O8" value="12" lower_limit="8.62" upper_limit="17"/>
                    <measurement group_id="O9" value="4.93" lower_limit="3.35" upper_limit="7.25"/>
                    <measurement group_id="O10" value="4.05" lower_limit="2.93" upper_limit="5.59"/>
                    <measurement group_id="O11" value="6.73" lower_limit="4.88" upper_limit="9.28"/>
                    <measurement group_id="O12" value="5.53" lower_limit="4.07" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day43/Day1(N=43,53,48,52,49,53,46,46,39,53,55,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="43" upper_limit="81"/>
                    <measurement group_id="O2" value="82" lower_limit="62" upper_limit="109"/>
                    <measurement group_id="O3" value="23" lower_limit="17" upper_limit="31"/>
                    <measurement group_id="O4" value="18" lower_limit="13" upper_limit="25"/>
                    <measurement group_id="O5" value="21" lower_limit="15" upper_limit="30"/>
                    <measurement group_id="O6" value="14" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O7" value="7.1" lower_limit="5.21" upper_limit="9.69"/>
                    <measurement group_id="O8" value="10" lower_limit="7.61" upper_limit="14"/>
                    <measurement group_id="O9" value="6.04" lower_limit="4.32" upper_limit="8.45"/>
                    <measurement group_id="O10" value="4.14" lower_limit="3.07" upper_limit="5.56"/>
                    <measurement group_id="O11" value="6.57" lower_limit="4.90" upper_limit="8.80"/>
                    <measurement group_id="O12" value="6.2" lower_limit="4.68" upper_limit="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day183/ Day1,N=38,44,42,48,50,47,40,44,37,52,54,58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.96" lower_limit="7.25" upper_limit="14"/>
                    <measurement group_id="O2" value="17" lower_limit="13" upper_limit="23"/>
                    <measurement group_id="O3" value="7.18" lower_limit="5.32" upper_limit="9.70"/>
                    <measurement group_id="O4" value="6.76" lower_limit="5.02" upper_limit="9.10"/>
                    <measurement group_id="O5" value="8.19" lower_limit="6.12" upper_limit="11"/>
                    <measurement group_id="O6" value="6.38" lower_limit="4.72" upper_limit="8.62"/>
                    <measurement group_id="O7" value="3.98" lower_limit="2.87" upper_limit="5.51"/>
                    <measurement group_id="O8" value="5.23" lower_limit="3.86" upper_limit="7.09"/>
                    <measurement group_id="O9" value="4.30" lower_limit="3.08" upper_limit="6.00"/>
                    <measurement group_id="O10" value="2.69" lower_limit="2.03" upper_limit="3.55"/>
                    <measurement group_id="O11" value="3.82" lower_limit="2.90" upper_limit="5.03"/>
                    <measurement group_id="O12" value="3.56" lower_limit="2.73" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366/Day1,N=37,43,38,48,50,47,38,41,37,53,52,58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" lower_limit="3.22" upper_limit="6.42"/>
                    <measurement group_id="O2" value="8.26" lower_limit="6.02" upper_limit="11"/>
                    <measurement group_id="O3" value="4.09" lower_limit="2.91" upper_limit="5.75"/>
                    <measurement group_id="O4" value="4.43" lower_limit="3.20" upper_limit="6.14"/>
                    <measurement group_id="O5" value="4.20" lower_limit="3.06" upper_limit="5.78"/>
                    <measurement group_id="O6" value="4.15" lower_limit="2.98" upper_limit="5.77"/>
                    <measurement group_id="O7" value="2.73" lower_limit="2.00" upper_limit="3.73"/>
                    <measurement group_id="O8" value="4.21" lower_limit="3.13" upper_limit="5.67"/>
                    <measurement group_id="O9" value="3.03" lower_limit="2.22" upper_limit="4.14"/>
                    <measurement group_id="O10" value="1.69" lower_limit="1.32" upper_limit="2.18"/>
                    <measurement group_id="O11" value="2.35" lower_limit="1.82" upper_limit="3.04"/>
                    <measurement group_id="O12" value="2.37" lower_limit="1.86" upper_limit="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 through Day 366.</time_frame>
      <desc>All solicited AEs and unsolicited AEs were collected from Day 1 to Day 7; any unsolicited AEs, any SAEs, medically attended AEs, AEs leading to withdrawal from the study, AESI and NOCD were collected from Day 1 (from 30 minutes) to Day 366 after every vaccination.
Analysis was done on the safety data sets.</desc>
      <group_list>
        <group group_id="E1">
          <title>A/H3N2C + 1/2 MF59 Age Group: 3 TO &lt;9 YEARS</title>
          <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="E2">
          <title>A/H3N2C + MF59 Age Group: 3 TO &lt;9 YEARS</title>
          <description>Subjects 3 to &lt;9 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="E3">
          <title>A/H3N2C Age Group: 3 TO &lt;9 YEARS</title>
          <description>Subjects 3 to &lt;9 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
        <group group_id="E4">
          <title>A/H3N2C + 1/2 MF59 Age Group: 9 TO &lt;18 YEARS</title>
          <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="E5">
          <title>A/H3N2C + MF59 Age Group: 9 TO &lt;18 YEARS</title>
          <description>Subjects 9 to &lt;18 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="E6">
          <title>A/H3N2C Age Group: 9 TO &lt;18 YEARS</title>
          <description>Subjects 9 to &lt;18 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
        <group group_id="E7">
          <title>A/H3N2C + 1/2 MF59 Age Group: 18 TO &lt;65 YEARS</title>
          <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="E8">
          <title>A/H3N2C + MF59 Age Group: 18 TO &lt;65 YEARS</title>
          <description>Subjects 18 to &lt;65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="E9">
          <title>A/H3N2C Age Group: 18 TO &lt;65 YEARS</title>
          <description>Subjects 18 to &lt;65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
        <group group_id="E10">
          <title>A/H3N2C + 1/2 MF59 Age Group: &gt;=65 YEARS</title>
          <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 3.75µg antigen adjuvanted with half dose MF59.</description>
        </group>
        <group group_id="E11">
          <title>A/H3N2C + MF59 Age Group: &gt;=65 YEARS</title>
          <description>Subjects ≥65 years old received two injections of cell-culture derived H3N2c vaccine, each dose containing 7.5 µg H3N2c antigen adjuvanted with full dose MF59.</description>
        </group>
        <group group_id="E12">
          <title>A/H3N2C Age Group: &gt;=65 YEARS</title>
          <description>Subjects ≥65 years old received two injections of a non-adjuvanted cell-culture derived H3N2c vaccine, each dose containing 15 µg antigen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>SURGICAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="43" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="30" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="33" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="31" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="32" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>INJECTION SITE BRUISING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="22" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="23" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>EATING DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

